Reported practice is informative without being proof that the most common practice is best.
What the study found
An online survey asked palliative physicians in Norway, Denmark and the United Kingdom about midazolam indications, dosing and administration. The study described clinical approaches across the participating settings.
A multinational questionnaire is not an outcome trial
The survey sampled palliative-care physicians in Norway, Denmark and the United Kingdom. Its purpose was to describe indications, dosing and use across settings. Low response and limited opportunities for individualized answers restrict how well the responses represent wider practice. Even experienced clinicians’ reported preferences cannot show which regimen produced the best comfort or communication outcomes in otherwise comparable patients.
Limits of interpretation
The response rate was low and the number of participants limited. Respondents’ accounts were not an audit of every administration or a randomized comparison of symptom relief and adverse events. Country differences can reflect services and patient populations.
Implications for case review
Identify the surveyed clinicians and the clinical goal before invoking a practice pattern. The survey cannot establish an individually appropriate dose or prove that a deviation from the common response was improper. Actual symptoms, proportionality, response and monitoring require case-specific review.
Source and related reading
Source: PMC11276578, supplied full-text paper. Findings are paraphrased; forensic implications are an interpretation.
Related: Palliative Sedation Interviews Distinguish Treatment Intent From Expected Sedative Effects.
Leave a Reply